SI3470086T1 - Pirolobenzodiazepini in njihovi konjugati - Google Patents

Pirolobenzodiazepini in njihovi konjugati

Info

Publication number
SI3470086T1
SI3470086T1 SI201331845T SI201331845T SI3470086T1 SI 3470086 T1 SI3470086 T1 SI 3470086T1 SI 201331845 T SI201331845 T SI 201331845T SI 201331845 T SI201331845 T SI 201331845T SI 3470086 T1 SI3470086 T1 SI 3470086T1
Authority
SI
Slovenia
Prior art keywords
pyrrolobenzodiazepines
conjugates
Prior art date
Application number
SI201331845T
Other languages
English (en)
Inventor
Philip Wilson Howard
Original Assignee
Medimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Limited filed Critical Medimmune Limited
Publication of SI3470086T1 publication Critical patent/SI3470086T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI201331845T 2012-10-12 2013-10-11 Pirolobenzodiazepini in njihovi konjugati SI3470086T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261712924P 2012-10-12 2012-10-12
EP18187765.5A EP3470086B1 (en) 2012-10-12 2013-10-11 Pyrrolobenzodiazepines and conjugates thereof

Publications (1)

Publication Number Publication Date
SI3470086T1 true SI3470086T1 (sl) 2021-03-31

Family

ID=49474386

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201331845T SI3470086T1 (sl) 2012-10-12 2013-10-11 Pirolobenzodiazepini in njihovi konjugati
SI201331325T SI2906248T1 (sl) 2012-10-12 2013-10-11 Pirolobenzodiazepini in njihovi konjugati

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201331325T SI2906248T1 (sl) 2012-10-12 2013-10-11 Pirolobenzodiazepini in njihovi konjugati

Country Status (24)

Country Link
US (1) US9415117B2 (sl)
EP (2) EP2906248B1 (sl)
JP (2) JP6367811B2 (sl)
KR (3) KR102138220B1 (sl)
CN (2) CN104703630A (sl)
AU (1) AU2013328674B2 (sl)
BR (1) BR112015008251B1 (sl)
CA (2) CA2885315C (sl)
CY (2) CY1121390T1 (sl)
DK (2) DK3470086T3 (sl)
ES (2) ES2713164T3 (sl)
HK (1) HK1213183A1 (sl)
HR (2) HRP20190366T1 (sl)
HU (2) HUE043738T4 (sl)
LT (2) LT3470086T (sl)
MX (2) MX362004B (sl)
NZ (2) NZ705910A (sl)
PL (2) PL3470086T3 (sl)
PT (2) PT2906248T (sl)
RS (2) RS61294B1 (sl)
SI (2) SI3470086T1 (sl)
TR (1) TR201902494T4 (sl)
WO (1) WO2014057073A1 (sl)
ZA (1) ZA201501781B (sl)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
JP5870400B2 (ja) 2010-04-15 2016-03-01 シアトル ジェネティクス，インコーポレーテッド 標的化ピロロベンゾジアゼピンコンジュゲート
EP2789622B1 (en) 2010-04-15 2017-03-01 MedImmune Limited Pyrrolobenzodiazepines used to treat proliferative diseases
CN103987718A (zh) 2011-09-20 2014-08-13 斯皮罗根有限公司 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓
EP2751110B1 (en) 2011-10-14 2017-04-19 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases
SG11201401021TA (en) 2011-10-14 2014-08-28 Spirogen Sarl Pyrrolobenzodiazepines
ES2687246T3 (es) 2011-10-14 2018-10-24 Seattle Genetics, Inc. Pirrolobenzodiazepinas y conjugados dirigidos
EP2753178B1 (en) 2011-10-14 2017-12-06 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
US9464141B2 (en) * 2012-08-02 2016-10-11 Genentech, Inc. Anti-ETBR antibodies and immunoconjugates
CA2885305C (en) 2012-10-12 2019-11-12 Spirogen Sarl Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
TR201902494T4 (tr) 2012-10-12 2019-03-21 Medimmune Ltd Pirrolobenzodiazepinler ve onların konjugatları.
CA2941485C (en) 2012-10-12 2018-06-12 Philip Wilson Howard Pyrrolobenzodiazepines and conjugates thereof
JP6392764B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
SI2906298T1 (sl) 2012-10-12 2018-12-31 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
WO2014057113A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine - anti-psma antibody conjugates
JP6527466B2 (ja) 2012-12-21 2019-06-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体
CN105189507A (zh) 2012-12-21 2015-12-23 斯皮罗根有限公司 吡咯并苯并二氮杂卓及其结合物
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
SG11201507214SA (en) 2013-03-13 2015-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
AU2014283185B2 (en) * 2013-06-21 2019-05-02 Innate Pharma Enzymatic conjugation of polypeptides
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CN114106185A (zh) 2014-09-12 2022-03-01 基因泰克公司 抗her2抗体和免疫缀合物
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
BR112017014599A2 (pt) 2015-01-14 2018-01-16 Bristol-Myers Squibb Company dímeros de benzodiazepina, conjugados dos mesmos, e métodos de preparação e uso
TW201632532A (zh) 2015-01-14 2016-09-16 必治妥美雅史谷比公司 伸雜芳基－橋聯苯并二氮呯二聚體，其共軛物及製造及使用方法
GB201506394D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506405D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
AU2016284340A1 (en) 2015-06-23 2018-02-08 Bristol-Myers Squibb Company Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
TWI778491B (zh) 2015-11-30 2022-09-21 美商輝瑞股份有限公司 位點專一性ｈｅｒ２抗體藥物共軛體
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US10934359B2 (en) 2016-04-21 2021-03-02 Abbvie Stemcentrx Llc Anti-BMPR1B antibodies and methods of use
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201132A2 (en) 2016-05-18 2017-11-23 Mersana Therapeutics, Inc. Pyrrolobenzodiazepines and conjugates thereof
US10526294B2 (en) 2016-06-24 2020-01-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepines and conjugates thereof
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201619490D0 (en) * 2016-11-17 2017-01-04 Medimmune Ltd Pyrrolobenzodiazepine conjugates
EP3348560A1 (en) * 2017-01-16 2018-07-18 Spago Nanomedical AB Chemical compounds for coating of nanostructures
LT3544636T (lt) 2017-02-08 2021-06-25 Adc Therapeutics Sa Pirolobenzodiazepino-antikūno konjugatai
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
HUE059828T2 (hu) 2017-04-18 2023-01-28 Medimmune Ltd Pirrolobenzodiazepin konjugátumok
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
BR112019026564A2 (pt) 2017-06-14 2020-06-30 Adc Therapeutics Sa regimes de dosagem para a administração de um adc anti-cd19
AU2018316532B2 (en) 2017-08-18 2022-11-24 Medimmune Limited Pyrrolobenzodiazepine conjugates
EP3690038A4 (en) 2017-09-29 2021-05-19 Daiichi Sankyo Company, Limited ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
JP2021502969A (ja) 2017-11-14 2021-02-04 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン複合体
EP3717021A1 (en) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CU24558B1 (es) * 2017-11-28 2021-12-08 Ct Inmunologia Molecular Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados
TW201929908A (zh) 2017-12-21 2019-08-01 美商梅爾莎納醫療公司 吡咯并苯并二氮呯抗體共軛物
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201902495D0 (en) 2019-02-25 2019-04-10 Medimmune Ltd Methods of synthesis and intermediates
AU2020265679A1 (en) 2019-04-30 2021-12-23 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
EP4013494A1 (en) 2019-08-12 2022-06-22 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
WO2021080608A1 (en) 2019-10-25 2021-04-29 Medimmune, Llc Branched moiety for use in conjugates
EP4294846A1 (en) * 2021-02-19 2023-12-27 Janssen Biotech, Inc. Materials and methods for targeting regulatory t cells for enhancing immune surveillance
KR102285542B1 (ko) 2021-03-09 2021-08-04 주식회사 레젠 투광등용 리플렉터 및 이를 가진 투광등
WO2023173096A1 (en) * 2022-03-11 2023-09-14 Sigma-Aldrich Co. Llc Pyrrolobenzodiazepine intermediates and uses thereof

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361742A (en) 1964-12-07 1968-01-02 Hoffmann La Roche 5-oxo-1h-pyrrolo-[2, 1-c][1, 4]-benzodiazepin-2-crylamides
US3523941A (en) 1967-03-06 1970-08-11 Hoffmann La Roche Benzodiazepine compounds and process for their preparation
US3524849A (en) 1967-10-27 1970-08-18 Hoffmann La Roche Process for the preparation of pyrrolo-benzodiazepine acrylamides and intermediates useful therein
FR2027356A1 (en) 1968-12-30 1970-09-25 Fujisawa Pharmaceutical Co Benzodiazepinone antibiotics
JPS4843755B1 (sl) 1969-06-26 1973-12-20
IL33558A (en) 1968-12-30 1973-10-25 Fujisawa Pharmaceutical Co Antibiotic pyrrolo-benzodiazepine compound,its derivatives and processes for their production
JPS5382792U (sl) 1976-12-10 1978-07-08
JPS585916B2 (ja) 1977-12-27 1983-02-02 株式会社ミドリ十字 新規ベンゾジアゼピン系化合物
JPS5615289A (en) 1979-07-17 1981-02-14 Green Cross Corp:The Novel benzodiazepinnbased compound 3
JPH0353356Y2 (sl) 1981-02-06 1991-11-21
CA1173441A (en) 1981-02-27 1984-08-28 Hoffmann-La Roche Limited Imidazodiazepines
CA1185602A (en) 1981-02-27 1985-04-16 Emilio Kyburz Imidazodiazepines
CA1184175A (en) 1981-02-27 1985-03-19 Walter Hunkeler Imidazodiazepines
JPS58180487A (ja) 1982-04-16 1983-10-21 Kyowa Hakko Kogyo Co Ltd 抗生物質ｄｃ−８１およびその製造法
JPS58180487U (ja) 1982-05-28 1983-12-02 松下電工株式会社 光線式報知器の組立体
US4427588A (en) 1982-11-08 1984-01-24 Bristol-Myers Company Process for conversion of oxotomaymycin to tomaymycin
US4427587A (en) 1982-11-10 1984-01-24 Bristol-Myers Company Total synthesis of antitumor antibiotics BBM-2040A and BBM-2040B
JPS59152329A (ja) 1983-02-17 1984-08-31 Green Cross Corp:The 局所障害抑制剤
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
FR2586683B1 (fr) 1985-08-29 1988-07-01 Centre Nat Rech Scient Nouveaux derives de neothramycine, leur procede de preparation et leur application en tant que medicaments
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
JP2660201B2 (ja) 1988-08-05 1997-10-08 塩野義製薬株式会社 新規ピロロ［１，４］ベンゾジアゼピン誘導体および老人性痴呆薬
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
GB9205051D0 (en) 1992-03-09 1992-04-22 Cancer Res Campaign Tech Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them
FR2696176B1 (fr) 1992-09-28 1994-11-10 Synthelabo Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
GB9316162D0 (en) 1993-08-04 1993-09-22 Zeneca Ltd Fungicides
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
AU5094699A (en) 1998-07-08 2000-02-01 E-Ink Corporation Methods for achieving improved color in microencapsulated electrophoretic devices
GB9818730D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collections of compounds
GB9818732D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collection of compounds
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
DE69930328T2 (de) 1998-08-27 2006-12-14 Spirogen Ltd., Ryde Dimere Pyrrolobenzodiazepine
US6909006B1 (en) 1999-08-27 2005-06-21 Spirogen Limited Cyclopropylindole derivatives
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
ATE422369T1 (de) 1999-12-24 2009-02-15 Genentech Inc Verfahren und zusammensetzungen zur verlängerung der entsorgungshalbwertszeit von biowirksamen verbindungen
DK1320522T3 (da) 2000-09-19 2006-04-03 Moses Lee Achirale analoger af CC-1065 og af duocarmyciner samt præparater og metoder til anvendelse deraf
US6362331B1 (en) 2001-03-30 2002-03-26 Council Of Scientific And Industrial Research Process for the preparation of antitumor agents
US6660856B2 (en) 2002-03-08 2003-12-09 Kaohsiung Medical University Synthesis of pyrrolo[2,1-c][1,4]benzodiazepine analogues
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
US20040138269A1 (en) 2002-10-11 2004-07-15 Sugen, Inc. Substituted pyrroles as kinase inhibitors
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
EP1608664B1 (en) 2003-03-31 2009-01-28 Council of Scientific and Industrial Research Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents and process thereof
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
GB0416511D0 (en) 2003-10-22 2004-08-25 Spirogen Ltd Pyrrolobenzodiazepines
EP1675857B1 (en) 2003-10-22 2011-07-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
JP5020636B2 (ja) 2003-11-06 2012-09-05 シアトル ジェネティックス， インコーポレイテッド リガンドに結合体化可能なモノメチルバリン化合物
WO2005079479A2 (en) 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
GB0404578D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
US7741319B2 (en) 2004-03-01 2010-06-22 Spirogen Limited 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines
GB0404574D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Amino acids
GB0404577D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
DE102004010943A1 (de) 2004-03-03 2005-09-29 Degussa Ag Verfahren zur Herstellung von N-geschützten 4-Ketprolinderivaten
US7528126B2 (en) 2004-03-09 2009-05-05 Spirogen Limited Pyrrolobenzodiazepines
FR2869231B1 (fr) 2004-04-27 2008-03-14 Sod Conseils Rech Applic Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
GB0410725D0 (en) 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
WO2006068325A2 (en) 2004-12-24 2006-06-29 Showa Denko K. K. Production method of thermoelectric semiconductor alloy, thermoelectric conversion module and thermoelectric power generating device
EP2388271A3 (en) 2005-02-03 2012-08-01 Antitope Limited Human Antibodies and Proteins
EP1871418B1 (en) 2005-04-19 2014-03-19 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
PT1879901E (pt) 2005-04-21 2010-03-29 Spirogen Ltd Pirrolobenzodiazepinas
DE602006006199D1 (de) 2005-10-05 2009-05-20 Spirogen Ltd 4-ä4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo ä2, 1-cüä1,4übenzodiazepin-8-yloxy)-butyrylaminoü-1h-pyrrol-2-carbonsäurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung
US20070154906A1 (en) 2005-10-05 2007-07-05 Spirogen Ltd. Methods to identify therapeutic candidates
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
PT1813614E (pt) 2006-01-25 2012-01-09 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina
BRPI0714871A2 (pt) 2006-07-18 2013-05-07 Sanofi Aventis anticorpo antagonista para o tratamento de cÂncer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2008050140A2 (en) 2006-10-27 2008-05-02 Spirogen Limited Compounds for treatment of parasitic infection
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
AU2008251608B2 (en) 2007-05-08 2014-03-27 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
SI2019104T1 (sl) 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
BRPI0818780A2 (pt) 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
GB0722087D0 (en) 2007-11-09 2007-12-19 Spirogen Ltd Polyamides
GB0722088D0 (en) 2007-11-09 2007-12-19 Spirogen Ltd Pyrrolobenzodiazepines
EP2244729B1 (en) * 2008-01-18 2016-11-02 MedImmune, LLC Cysteine engineered antibodies for site-specific conjugation
PL2842575T3 (pl) 2008-03-18 2018-02-28 Seattle Genetics, Inc. Koniugaty aurystatyny lek łącznik
GB0813432D0 (en) 2008-07-22 2008-08-27 Spirogen Ltd Pyrrolobenzodiazepines
WO2010043380A1 (en) 2008-10-15 2010-04-22 Zimmer Gmbh Intramedullary nail
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
GB0819097D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
MX2011008328A (es) 2009-02-05 2011-11-04 Immunogen Inc Derivados novedosos de benzodiacepina.
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
WO2011038159A2 (en) 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
US9040526B2 (en) 2010-02-09 2015-05-26 Bristol-Myers Squibb Company Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity
EP2789622B1 (en) * 2010-04-15 2017-03-01 MedImmune Limited Pyrrolobenzodiazepines used to treat proliferative diseases
WO2011130615A2 (en) 2010-04-15 2011-10-20 Dr. Reddy's Laboratories Ltd. Preparation of lacosamide
JP5870400B2 (ja) * 2010-04-15 2016-03-01 シアトル ジェネティクス，インコーポレーテッド 標的化ピロロベンゾジアゼピンコンジュゲート
GB201006340D0 (en) 2010-04-15 2010-06-02 Spirogen Ltd Synthesis method and intermediates
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
MX346635B (es) 2011-02-15 2017-03-27 Immunogen Inc Derivados citotoxicos de la benzodiazepina.
CN103987718A (zh) * 2011-09-20 2014-08-13 斯皮罗根有限公司 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓
SG11201401021TA (en) 2011-10-14 2014-08-28 Spirogen Sarl Pyrrolobenzodiazepines
CN103987407B (zh) 2011-10-14 2016-08-24 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其偶联物
EP2753178B1 (en) 2011-10-14 2017-12-06 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
ES2687246T3 (es) 2011-10-14 2018-10-24 Seattle Genetics, Inc. Pirrolobenzodiazepinas y conjugados dirigidos
EP2751110B1 (en) 2011-10-14 2017-04-19 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases
JP6166728B2 (ja) 2011-10-14 2017-07-19 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
KR101960130B1 (ko) 2012-04-30 2019-03-19 메디뮨 리미티드 피롤로벤조디아제핀
JP6157596B2 (ja) 2012-04-30 2017-07-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン
EP2869850B1 (en) 2012-07-09 2017-08-23 Genentech, Inc. Immunoconjugates comprising anti-cd79b antibodies
EP2869849A1 (en) 2012-07-09 2015-05-13 Genentech, Inc. Immunoconjugates comprising anti-cd22 antibodies
US9464141B2 (en) 2012-08-02 2016-10-11 Genentech, Inc. Anti-ETBR antibodies and immunoconjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
LT2906252T (lt) 2012-10-12 2017-09-11 Adc Therapeutics Sa Pirolobenzodiazepino-anti-her2 antikūno konjugatai
WO2014057118A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
JP6392764B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
SI2906298T1 (sl) 2012-10-12 2018-12-31 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo
CA2941485C (en) 2012-10-12 2018-06-12 Philip Wilson Howard Pyrrolobenzodiazepines and conjugates thereof
TR201902494T4 (tr) 2012-10-12 2019-03-21 Medimmune Ltd Pirrolobenzodiazepinler ve onların konjugatları.
CA2885305C (en) 2012-10-12 2019-11-12 Spirogen Sarl Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
WO2014057113A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine - anti-psma antibody conjugates
JP6527466B2 (ja) 2012-12-21 2019-06-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体
CN105189507A (zh) 2012-12-21 2015-12-23 斯皮罗根有限公司 吡咯并苯并二氮杂卓及其结合物
LT2958944T (lt) 2013-02-22 2019-07-10 Abbvie Stemcentrx Llc Antikūno prieš dll3 ir pbd konjugatai bei jų panaudojimas
EP2968585B1 (en) 2013-03-13 2018-07-18 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
SG11201507214SA (en) 2013-03-13 2015-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2014174111A1 (en) 2013-04-26 2014-10-30 Pierre Fabre Medicament Axl antibody-drug conjugate and its use for the treatment of cancer
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US20160256561A1 (en) 2013-10-11 2016-09-08 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
KR102337414B1 (ko) 2013-12-16 2021-12-10 제넨테크, 인크. 펩타이드 모방체 화합물 및 이의 항체-약물 컨쥬게이트
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates

Also Published As

Publication number Publication date
BR112015008251B1 (pt) 2023-09-26
HK1213183A1 (zh) 2016-06-30
AU2013328674B2 (en) 2017-06-22
PT3470086T (pt) 2021-02-01
CN110256469B (zh) 2022-05-17
LT3470086T (lt) 2021-02-25
CY1121390T1 (el) 2020-05-29
MX366303B (es) 2019-07-04
JP6516909B2 (ja) 2019-05-22
MX362004B (es) 2019-01-03
BR112015008251A2 (pt) 2017-07-04
SI2906248T1 (sl) 2019-02-28
JP2018168182A (ja) 2018-11-01
ZA201501781B (en) 2016-06-29
JP2015533141A (ja) 2015-11-19
CN110256469A (zh) 2019-09-20
ES2713164T3 (es) 2019-05-20
KR102138220B1 (ko) 2020-07-27
HUE043738T2 (hu) 2019-09-30
AU2013328674A1 (en) 2015-04-02
CN104703630A (zh) 2015-06-10
EP3470086B1 (en) 2020-11-25
PL3470086T3 (pl) 2021-05-31
CA3060520A1 (en) 2014-04-17
HRP20190366T1 (hr) 2019-04-19
EP3470086A1 (en) 2019-04-17
DK2906248T3 (en) 2019-03-04
RS58203B1 (sr) 2019-03-29
KR20190126197A (ko) 2019-11-08
DK3470086T3 (da) 2020-12-21
EP2906248A1 (en) 2015-08-19
LT2906248T (lt) 2019-02-11
WO2014057073A1 (en) 2014-04-17
US9415117B2 (en) 2016-08-16
EP2906248B1 (en) 2018-12-05
PT2906248T (pt) 2019-03-04
JP6367811B2 (ja) 2018-08-01
HUE052835T2 (hu) 2021-05-28
NZ705910A (en) 2018-09-28
CA3060520C (en) 2022-05-17
KR20150083994A (ko) 2015-07-21
RS61294B1 (sr) 2021-02-26
TR201902494T4 (tr) 2019-03-21
NZ745069A (en) 2019-05-31
PL2906248T3 (pl) 2019-05-31
HUE043738T4 (hu) 2020-05-28
CY1123778T1 (el) 2022-05-27
CA2885315C (en) 2020-06-23
CA2885315A1 (en) 2014-04-17
HRP20210126T1 (hr) 2021-03-19
KR20200003278A (ko) 2020-01-08
ES2847050T3 (es) 2021-07-30
US20140120118A1 (en) 2014-05-01
MX2015004560A (es) 2015-07-21

Similar Documents

Publication Publication Date Title
HRP20190366T1 (hr) Pirolobenzodiazepini i njihovi konjugati
IL245268B (en) Pyrrolobenzodiazepines and their conjugates
HK1216638A1 (zh) 吡咯並苯並二氮雜卓及其結合物
HK1219658A1 (zh) 吡咯並苯並二氮雜卓及其結合物
HK1219651A1 (zh) 吡咯並苯並二氮雜卓以及其結合物
HK1214140A1 (zh) 吡咯並苯並二氮雜卓和其結合物
HK1195017A1 (zh) 吡咯並苯並二氮雜卓及其偶聯物
PT2920167T (pt) Compostos de hidrazinil-indol e conjugados
GB201317982D0 (en) Pyrrolobenzodiazepines and conjugates thereof
GB201317981D0 (en) Pyrrolobenzodiazepines and conjugates thereof
EP2885318A4 (en) PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF